Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Molecular characterization of a locus required for hyaluronic acid capsule production in group A streptococci.
Dougherty BA
,
van de Rijn I
.
???displayArticle.abstract???
To characterize the production of hyaluronate capsule by the membrane-associated enzyme hyaluronate synthase (HAS), group A streptococci from a recent outbreak of acute rheumatic fever were mutagenized via Tn916 insertion. Acapsular transconjugants harboring multiple, nontandem copies of the transposon were identified and found to lack HAS activity (less than 1% of wild-type levels). Generalized transduction was then performed to determine which Tn916 insertion was responsible for the HAS- phenotype. These marker exchange experiments resulted in the isolation of two distinct classes of acapsular transductants, designated WF61 and WF62. Both transductants also lacked significant HAS activity, and excision of the transposon from WF62 restored capsular hyaluronate production. Southern analysis of WF61 DNA demonstrated a large deletion of genomic DNA adjacent to the Tn916 insertion. This deletion event is presumably responsible for the observed stability of the acapsular phenotype of WF61. Further analyses of transductant whole-cell DNA indicated that the transposon insertions of WF61 and WF62 were separated by 2.5 kb. These studies define a locus required for hyaluronate capsule production in group A streptococci. Further genetic analysis of this locus has identified a gene required for HAS activity which wasd inactivated by TN916 in WF62 and deleted in WF61.
Caparon,
Genetic manipulation of pathogenic streptococci.
1991, Pubmed
Caparon,
Genetic manipulation of pathogenic streptococci.
1991,
Pubmed
Chang,
Construction and characterization of amplifiable multicopy DNA cloning vehicles derived from the P15A cryptic miniplasmid.
1978,
Pubmed
Clewell,
Conjugative transposons and the dissemination of antibiotic resistance in streptococci.
1986,
Pubmed
Clewell,
Sequence analysis of termini of conjugative transposon Tn916.
1988,
Pubmed
Fillit,
Sera from patients with poststreptococcal glomerulonephritis contain antibodies to glomerular heparan sulfate proteoglycan.
1985,
Pubmed
Fillit,
Induction of antibodies to hyaluronic acid by immunization of rabbits with encapsulated streptococci.
1986,
Pubmed
Fillit,
Immunogenicity of liposome-bound hyaluronate in mice. At least two different antigenic sites on hyaluronate are identified by mouse monoclonal antibodies.
1988,
Pubmed
Franke,
Evidence for a chromosome-borne resistance transposon (Tn916) in Streptococcus faecalis that is capable of "conjugal" transfer in the absence of a conjugative plasmid.
1981,
Pubmed
Gawron-Burke,
Regeneration of insertionally inactivated streptococcal DNA fragments after excision of transposon Tn916 in Escherichia coli: strategy for targeting and cloning of genes from gram-positive bacteria.
1984,
Pubmed
Glaser,
THE ENZYMATIC SYNTHESIS IN VITRO OF HYALURONIC ACID CHAINS.
1955,
Pubmed
HIRSCH,
Studies of phagocytosis of group A streptococci by polymorphonuclear leucocytes in vitro.
1960,
Pubmed
Jann,
Structure and biosynthesis of the capsular antigens of Escherichia coli.
1990,
Pubmed
Kass,
THE ROLE OF THE MUCOID POLYSACCHARIDE (HYALURONIC ACID) IN THE VIRULENCE OF GROUP A HEMOLYTIC STREPTOCOCCI.
1944,
Pubmed
Kehoe,
Cloning and expression in Escherichia coli of the streptolysin O determinant from Streptococcus pyogenes: characterization of the cloned streptolysin O determinant and demonstration of the absence of substantial homology with determinants of other thiol-activated toxins.
1984,
Pubmed
MARKOVITZ,
The biosynthesis of hyaluronic acid by group A Streptococcus. VI. Biosynthesis from uridine nucleotides in cell-free extracts.
1959,
Pubmed
Nida,
Insertional inactivation of streptolysin S expression in Streptococcus pyogenes.
1983,
Pubmed
Prehm,
Isolation of streptococcal hyaluronate synthase.
1986,
Pubmed
,
Xenbase
ROTHBARD,
Protective effect of hyaluronidase and type-specific anti-M serum on experimental group A streptococcus infection in mice.
1948,
Pubmed
STOLLERMAN,
Accessory plasma factors involved in the bactericidal test for type-specific antibody to group A streptococci. I. A typical behavior of some human and rabbit bloods.
1958,
Pubmed
Shyamala,
Genome walking by single-specific-primer polymerase chain reaction: SSP-PCR.
1989,
Pubmed
Simpson,
Coregulation of type 12 M protein and streptococcal C5a peptidase genes in group A streptococci: evidence for a virulence regulon controlled by the virR locus.
1990,
Pubmed
Swift,
TYPING GROUP A HEMOLYTIC STREPTOCOCCI BY M PRECIPITIN REACTIONS IN CAPILLARY PIPETTES.
1943,
Pubmed
Triscott,
Solubilization of hyaluronic acid synthetic activity from streptococci and its activation with phospholipids.
1986,
Pubmed
Underhill,
Naturally-occurring antibodies which bind hyaluronate.
1982,
Pubmed
Veasy,
Resurgence of acute rheumatic fever in the intermountain area of the United States.
1987,
Pubmed
WILSON,
The relative importance of the capsule and the M-antigen in determining colony form of group A streptococci.
1959,
Pubmed
Wessels,
Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci.
1991,
Pubmed
Whitnack,
Hyaluronate capsule prevents attachment of group A streptococci to mouse peritoneal macrophages.
1981,
Pubmed
van de Rijn,
Streptococcal hyaluronic acid: proposed mechanisms of degradation and loss of synthesis during stationary phase.
1983,
Pubmed
van de Rijn,
Growth characteristics of group A streptococci in a new chemically defined medium.
1980,
Pubmed
